23andMe going private. Phase 2 Clinical Trials for Anti-Tumor Drug coming in July

- CEO of 23andMe, Anne Wojcicki, is considering buying out the company and taking it private - The company has an anti-cancer drug completing clinical trials on July 30, 2024 - Positive results from the cancer trial could significantly increase the company's market value - The CEO's decision to go private may indicate she knows something about upcoming developments - Opportunity for investors to either prevent the buyout or benefit from potential gains in cancer drug development by buying the stock (ticker: ME)